Navigation Links
Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research
Date:10/30/2007

ANN ARBOR, Mich., Oct. 30 /PRNewswire/ -- NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the addition of Joyce Sutcliffe, Ph.D., as vice president of research.

Sutcliffe brings 26 years of experience in the discovery and design of new antibiotics, with particular emphasis on understanding and overcoming antibiotic resistance. She joined the NanoBio team from Rib-X Pharmaceuticals, where she served as vice president of biology and chief research scientist.

During her tenure at Rib-X Pharmaceuticals and previously at Pfizer and Abbott, Sutcliffe focused on leveraging knowledge about target-based resistance to help design novel antibiotics that are potent against organisms with antibiotic resistance. She also led teams that evaluated efficacy and pharmacokinetics in animal disease models to ensure safety and compatibility with other drugs.

"Antibiotic resistance drives the need for new treatments against tenacious infectious microorganisms that continue to mutate," said Sutcliffe. "For example the rampant explosion of MRSA (methicillin-resistant Staphylococcus aureus) in the community has led to a need for safe anti- infectives. These bacteria are no longer resistant to just antibiotics but have become multidrug-resistant by adding other resistance mechanisms to their armamentarium.

"NanoBio's deep pipeline of topical anti-infectives and mucosal vaccines is particularly compelling, given the platform technology poses a very low risk of resistance while having broad antimicrobial activity against a wide range of infections," Sutcliffe said.

NanoBio's line of anti-infectives are designed to wage a two-pronged attack against bacteria, viruses, and fungi using safe detergents along with high-energy nanoemulsions to physically disrupt pathogen membranes and lyse microbes, said James Baker, Jr., M.D., founder and CSO of NanoBio Corporation. The absence of a specific metabolic target significantly reduces the likelihood of triggering resistant infections, he added.

"The addition of Dr. Sutcliffe, an internationally recognized anti- infective expert, will enable NanoBio to accelerate the number of product candidates we take into the clinic for preventing and treating a wide range of infections," said Baker.

About NanoBio

NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.


'/>"/>
SOURCE NanoBio Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Chemical-petroleum executive joins Virent Energy board
2. Schneider National exec joins TrafficCast board
3. Doyle joins governors in support of stem cell bill
4. Genomics researcher Hood joins NimbleGen board
5. Fergus joins Baird Venture Partners, Caden Bio
6. Meier joins Broadlook Technologies as COO
7. Prodesse joins forces with Invitrogen
8. Wisconsin joins price-fixing suit vs. D-RAM makers
9. Napier joins board of Third Wave Technologies
10. Schmidt rejoins Renaissance Learning
11. Tommy Thompson joins drug company as advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 On ... trading session at 5,817.69, down 0.07%; the Dow Jones ... and the S&P 500 closed at 2,345.96, marginally dropping ... sectors closed in green, 4 sectors finished in red, ... Friday, Stock-Callers.com has initiated reports coverage on the following ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... material that exhibits both viscous and elastic characteristics when deformed, which is identical ... exhibits properties to gently absorb compressive forces and return to its natural state ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
(Date:3/23/2017)...  BioPharmX Corporation (NYSE MKT: BPMX), a specialty ... today reported financial results for the quarter and ... an update on the company,s clinical development efforts ... are pleased to report that last year was ... Anja Krammer. "We achieved key clinical milestones and ...
Breaking Biology Technology:
(Date:3/7/2017)... England , March 7, 2017 Brandwatch , ... chosen by The Prince,s Trust to uncover insights to ... across The Trust. The UK,s leading youth charity will ... social campaign results and get a better understanding of the topics ... ...
(Date:3/2/2017)... 2017 Summary This report provides ... KGaA and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
(Date:2/28/2017)... --  Acuant , a leading provider of data capture ... new and core technologies building upon the acquisition of ... desktop Acuant FRM TM facial recognition and match ... manual review of identity documents by accredited professionals. ... most accurate capture software to streamline workflows by securely ...
Breaking Biology News(10 mins):